,

Oncothermia EHY-2000: Latest technology

Oncothermia EHY-2000: Latest technology

Oncological Nanothermia or Oncothermia is a non-invasive modulated electromagnetic hyperthermia method, adjuvant in cancer treatment, which promotes a natural regulatory process of the body.

The Oncotherm® brand was founded in 1988 by Professor Dr. András Szász, as an initiative for the development and research of the electro-hyperthermia method in cancer treatment.

Oncothermia treatment began in Germany 25 years ago, and is currently used in more than 25 countries. It is important to note that in Germany alone equipment has been installed in 4 hospitals and in more than 50 clinics working effectively. In addition, each year more than 100,000 treatments are performed worldwide.

The latest generation model in Oncothermia is: EHY-2000. Currently there are other models of devices, but they do not guarantee the results obtained and investigated by Dr. András Szász.

At the Barcelona Oncothermia Unit you will find the latest technology to offer you the best results.

,

Oncothermia receives the patent as a “tumor vaccine”

Oncothermia como patente cáncer

Oncothermia receives the patent as a “tumor vaccine”

This treatment alerts our immune system by checking the cancer cells.

The Oncothermia EHY-2000 plus device received the patent, US 20150217099 A1 in August 2015, describing this treatment as “a tumor vaccine”. It refers to “a vaccine” because it stimulates the immune system and radiofrequency promotes apoptosis or cell death of tumor cells.

Oncothermia is effective for the primary tumor and its metastases. Therefore, it has a local and systemic effect.

Procedure of action of the “vaccine”

The applied technique is called Modulated Electro-Hyperthermia (mEHT). The cancer cells in our body when treated with mEHT produce “heat shock proteins” when they are heated. This treatment alerts our immune system by checking the cancer cells. In this way, these cells are recognized by our immune system and eliminate them.

We all have approximately 1000 cancer cells that circulate in our body every day. Those with a weak immune system can develop a tumor.

In conclusion

For patients diagnosed with cancer, Oncothermia is an excellent option for immunotherapy to complement conventional treatments: surgery, chemotherapy or radiotherapy, in an integrative oncology framework.

You can obtain more information about the operation of Oncothermia for treatments in cancer patients through this link.

,

Oncothermia at the Congress of Radiotherapy Technicians (10-12 / 11/2017, Lisbon, Portugal)

Oncothermia at the Congress of Radiotherapy Technicians (10-12 / 11/2017, Lisbon, Portugal)

Filipe Cidade de Moura and Prof.András Szász

Oncothermia is an adjuvant treatment for cancer. It is present at an international level at events such as this congress and other conferences. At these scientific meetings, doctors, technicians and healthcare personnel give presentations to disseminate the results of clinical cases.

Congress in Lisboa

Therefore, on November 10-12, 2017, in Lisbon, took place the Congress of Radiotherapy Technicians (Congresso 2017art).

The congress was organized in different sections. Professor Szasz led the talk “Immunological effects with Oncothermia“, where he presented his latest research and results. Also, he detailed his studies on Oncothermia and the results in relation to the inhibitory effect on the natural activity of the malignant cells. Among other things he highlighted the stimulation of the patient’s immune response.

Objective of the research

Most of the radiation therapies act locally. The local control of the tumor is usually not enough for elongation of the survival time because the malignancy is systemic. The abscopal effect, together with immune-stimuli could extend the local method to systemic and could be effective against macro- and micrometastases, too. Our objective is presenting the abscopal effect of modulated electro-hyperthermia (mEHT, oncothermia).

References

https://www.justnews.pt/documentos/2015/image/file/17e/ProgramaCNART-2017.pdf

http://oncotherm.com/en/news-events/congresso-2017-art-profandras-szasz-was-invited-hold-lecture